Eisai
4523.T
₹2,123
Share price
-3.69%
Change (1 day)
-36.81%
Change (1 year)
Categories
Eisai is a Japanese pharmaceutical company that is engaged in the R&D of drugs for the treatment of dementia and Alzheimer.
Revenue for Eisai (4523.T)
Revenue in 2024 (TTM): ₹419.75 Billion
According to Eisai's latest financial reports the company's current revenue (TTM 
) is ₹436.29 Billion. In 2023 the company made a revenue of ₹440.39 Billion a decrease over the revenue in the year 2022 that were of ₹459.61 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Eisai from 2009 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | ₹419.75 B | -4.69% |
| 2023 | ₹440.39 B | -4.18% |
| 2022 | ₹459.61 B | -2.94% |
| 2021 | ₹473.52 B | -2.93% |
| 2020 | ₹487.81 B | 12.8% |
| 2019 | ₹432.45 B | 8.64% |
| 2018 | ₹398.07 B | 22.86% |
| 2017 | ₹324.00 B | -3.09% |
| 2016 | ₹334.34 B | 7.24% |
| 2015 | ₹311.77 B | -5.44% |
| 2014 | ₹329.72 B | -10.09% |
| 2013 | ₹366.71 B | -4.98% |
| 2012 | ₹385.93 B | -12.37% |
| 2011 | ₹440.43 B | 4.66% |
| 2010 | ₹420.83 B | 8.57% |
| 2009 | ₹387.61 B |